Greenwich LifeSciences annual return on equity
2020
2021
2022
2023
2024
2025
Greenwich LifeSciences Return on Equity (ROE) Growth & History (GLSI)
Greenwich LifeSciences's return on equity was −3,068.25% for fiscal 2025.
View full Greenwich LifeSciences company overviewGreenwich LifeSciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −3,068.25% | −2610.52 pp |
| 2024 | 2024-12-31 | −457.72% | −368.43 pp |
| 2023 | 2023-12-31 | −89.30% | −50.22 pp |
| 2022 | 2022-12-31 | −39.08% | −22.30 pp |
| 2021 | 2021-12-31 | −16.78% | −2.61 pp |
| 2020 | 2020-12-31 | −14.18% | — |
Greenwich LifeSciences quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −94.16% | +837.43 pp |
| Q1 2026 | 2026-03-31 | −201.20% | +293.75 pp |
| Q4 2025 | 2025-12-31 | −721.26% | −393.13 pp |
| Q3 2025 | 2025-09-30 | −266.11% | −216.95 pp |
| Q2 2025 | 2025-06-30 | −931.59% | −884.18 pp |
| Q1 2025 | 2025-03-31 | −494.95% | −453.11 pp |
| Q4 2024 | 2024-12-31 | −328.13% | −292.81 pp |
| Q3 2024 | 2024-09-30 | −49.16% | −24.63 pp |
| Q2 2024 | 2024-06-30 | −47.41% | −32.83 pp |
| Q1 2024 | 2024-03-31 | −41.84% | −24.77 pp |
| Q4 2023 | 2023-12-31 | −35.32% | −15.82 pp |
| Q3 2023 | 2023-09-30 | −24.53% | −10.20 pp |
| Q2 2023 | 2023-06-30 | −14.58% | −10.49 pp |
| Q1 2023 | 2023-03-31 | −17.07% | −8.57 pp |
| Q4 2022 | 2022-12-31 | −19.50% | −10.96 pp |
| Q3 2022 | 2022-09-30 | −14.32% | −11.33 pp |
| Q2 2022 | 2022-06-30 | −4.09% | −1.54 pp |
| Q1 2022 | 2022-03-31 | −8.50% | −6.42 pp |
| Q4 2021 | 2021-12-31 | −8.54% | −1.41 pp |
| Q3 2021 | 2021-09-30 | −3.00% | +12.54 pp |
| Q2 2021 | 2021-06-30 | −2.55% | — |
| Q1 2021 | 2021-03-31 | −2.08% | — |
| Q4 2020 | 2020-12-31 | −7.13% | — |
| Q3 2020 | 2020-09-30 | −15.53% | — |
Greenwich LifeSciences return on equity trends
Over the last five fiscal years, Greenwich LifeSciences's return on equity decreased from −14.18% to −3,068.25%, a change of −3054.07 percentage points. The latest reported quarter, Q2 2026, shows −94.16%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Greenwich LifeSciences source filings ↗